OGEN ORAGENICS INC
Pharmaceutical Preparations · NYSE · SEC CIK 1174940 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY11.8%
TTM EPS YoY-102.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-176.1%
ROA-120.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets66.7%
Debt / equity0.00x
Current ratio—
Interest coverage-547.81x
Cash quality & payout
Operating cash flow / net income0.96x
Accruals ratio-4.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | $37,653 | $131,521 | $86,987 |
| R&D expense | $2.39M | $4.11M | $15.49M | $10.07M | $10.59M |
| SG&A expense | $6.97M | $6.44M | $5.45M | $4.48M | $5.27M |
| Operating income | -$9.36M | -$10.56M | -$20.90M | -$14.42M | -$15.77M |
| Interest expense | $785,930 | $29,828 | $30,591 | $15,103 | $15,756 |
| Pretax income | -$9.98M | -$10.57M | -$20.66M | -$14.29M | -$15.71M |
| Income tax | -$136,910 | — | — | — | — |
| Net income | -$9.84M | -$10.57M | -$20.66M | -$14.29M | -$15.71M |
| EBITDA | — | — | -$20.88M | -$14.38M | -$15.73M |
| EPS (basic) | -4.56 | -47.88 | -9.18 | -7.11 | -8.09 |
| EPS (diluted) | -4.56 | -47.88 | -9.18 | -7.11 | -0.14 |
| Weighted avg. shares (diluted) | 2.16M | 220,731 | 2.25M | 2.01M | 112.92M |
| Banking | |||||
| Deposits | — | — | — | $17,940 | $17,940 |
| Balance sheet | |||||
| Cash & equivalents | $4.40M | $864,840 | $3.48M | $11.43M | $27.27M |
| Short-term investments | $4.00M | — | — | — | — |
| Current assets | $10.07M | $1.47M | $3.87M | $14.29M | $27.71M |
| PP&E, net | — | — | $0 | $121,062 | $45,708 |
| Total assets | $10.07M | $1.47M | $4.97M | $14.76M | $28.23M |
| Current liabilities | — | — | $1.80M | $1.60M | $1.45M |
| Total liabilities | $1.79M | $1.68M | $1.80M | $1.75M | $1.74M |
| Shareholders' equity | $8.28M | -$211,885 | $3.17M | $13.01M | $26.49M |
| Shares outstanding | 4.27M | 419,003 | 3.08M | 2.02M | 2.00M |
| Cash flow statement | |||||
| Operating cash flow | -$9.25M | -$8.60M | -$7.29M | -$15.23M | -$13.47M |
| Capital expenditure | — | — | — | $127,519 | $43,876 |
| Free cash flow | — | — | — | -$15.36M | -$13.51M |
| Investing cash flow | — | — | -$936,284 | -$115,519 | -$43,876 |
| Financing cash flow | $16.78M | $5.98M | $283,880 | -$494,916 | $23.14M |
| Depreciation & amortization | — | — | $27,391 | $44,667 | $41,237 |
| Stock-based compensation | $642,364 | $516,049 | $1.02M | $742,203 | $1.69M |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.